| Signal integration by the CYP1A1 promoter — a quantitative study P Schulthess, A Löffler, S Vetter, L Kreft, M Schwarz, A Braeuning, ... Nucleic Acids Research 43 (11), 5318-5330, 2015 | 37 | 2015 |
| Computer-assisted curation of a human regulatory core network from the biological literature P Thomas, P Durek, I Solt, B Klinger, F Witzel, P Schulthess, Y Mayer, ... Bioinformatics 31 (8), 1258-1266, 2015 | 18 | 2015 |
| Outside‐in systems pharmacology combines innovative computational methods with high‐throughput whole vertebrate studies P Schulthess, RC van Wijk, EHJ Krekels, JWT Yates, HP Spaink, ... CPT: Pharmacometrics & Systems Pharmacology 7 (5), 285-287, 2018 | 16 | 2018 |
| Frequency‐domain response analysis for quantitative systems pharmacology models P Schulthess, TM Post, J Yates, PH van der Graaf CPT: Pharmacometrics & Systems Pharmacology, 2017 | 8 | 2017 |
| Optimization of Cancer Treatment in the Frequency Domain P Schulthess, V Rottschäfer, JWT Yates, PH van der Graaf The AAPS journal 21 (6), 106, 2019 | 3 | 2019 |
| From reaction networks to information flow—Using modular response analysis to track information in signaling networks P Schulthess, N Blüthgen Methods in enzymology 500, 397-409, 2011 | 3 | 2011 |
| The pharmacokinetic and pharmacodynamic relationship between apraglutide and citrulline: a randomized, placebo-controlled, double-blind study in healthy volunteers F Bolognani, P Gal, M Moerland, A Kruithof, M van Gent, P Schulthess, ... Clinical Nutrition ESPEN 40, 413-414, 2020 | 2 | 2020 |
| Su559 POPULATION MODEL CONFIRMS PREDICTABLE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILE FOR APRAGLUTIDE-DATA FROM TWO RANDOMIZED PHASE 1 STUDIES F Bolognani, M Machacek, A Kruithof, ML de Kam, K Bergmann, ... Gastroenterology 160 (6), S-738, 2021 | 1 | 2021 |
| Population Model Confirms Predictable Pharmacokinetic (PK) And Pharmacodynamic (PD) Profile for Apraglutide: Data From Two Randomized Phase 1 Studies F Bolognani, M Machacek, A Kruithof, M de Kam, K Bergmann, ... TRANSPLANTATION 106 (9), S544-S544, 2022 | | 2022 |
| P7. 09: Population Model Confirms Predictable Pharmacokinetic (PK) And Pharmacodynamic (PD) Profile for Apraglutide: Data From Two Randomized Phase 1 Studies F Bolognani, M Machacek, A Kruithof, M de Kam, K Bergmann, ... Transplantation 106 (9S), S544, 2022 | | 2022 |
| Thermodynamic modeling explains the regulation of CYP1A1 expression in the liver P Schulthess Humboldt-Universität zu Berlin, Lebenswissenschaftliche Fakultät, 2016 | | 2016 |
| Signal integration by the CYP1A1 promoter-a quantitative study A Braeuning, P Schulthess, M Schwarz, N Bluethgen FEBS JOURNAL 282, 80-80, 2015 | | 2015 |
| A quantitative study of dual signal integration by the CYP1A1 promoter P Schulthess, A Loeffler, S Vetter, L Kreft, M Schwarz, A Braeuning, ... FEBS JOURNAL 282, 81-81, 2015 | | 2015 |
| Cooperativity Between Aryl Hydrocarbon Receptor and beta-catenin Binding Sites in CYP1A1 Induction P Schulthess, A Braeuning, A Loeffler, M Schwarz, N Bluethgen NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 386, S75-S75, 2013 | | 2013 |
| Interactions of signaling through the aryl hydrocarbon receptor and the β-catenin pathway in the regulation of CYP1A1 expression A Braeuning, P Schulthess, A Löffler, N Blüthgen, M Schwarz Toxicology Letters, S170, 2013 | | 2013 |
| Population Approach Group Europe Population Approach Group Europe P Schulthess | | |
Nils BlüthgenCharité Universitätsmedizin Berlin - IRI Life SciencesVerified email at charite.de
